RT Journal Article
SR Electronic
T1 Effectiveness of Ivermectin-Based Multidrug Therapy in Severe Hypoxic Ambulatory COVID-19 Patients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.07.06.21259924
DO 10.1101/2021.07.06.21259924
A1 Hazan, Sabine
A1 Dave, Sonya
A1 Gunaratne, Anoja W.
A1 Dolai, Sibasish
A1 Clancy, Robert L
A1 McCullough, Peter A.
A1 Borody, Thomas J.
YR 2021
UL http://medrxiv.org/content/early/2021/07/07/2021.07.06.21259924.abstract
AB Ivermectin is a safe, inexpensive and effective early COVID-19 treatment validated in 20+ RCTs. Having developed combination therapies for Helicobacter pylori, we tested various COVID-19 combinations and describe the most effective. In 24 consecutive COVID-19 subjects with high risk features, hypoxia and untreated moderate-severe symptoms averaging 9 days, we trialed this novel combination comprising ivermectin, doxycycline, zinc, and Vitamins D and C. It was highly effective. All subjects resolved symptoms in 11 days on average, and oxygen saturation improved in 24hrs (87.4% to 93.1%, p=0.001). Hospitalizations and deaths were significantly fewer (p<0.002 or 0.05, respectively) than in background-matched controls from the CDC database. Triple combination therapy is safe and effective even in moderate-severe patients with hypoxia treated in the outpatient setting.Trial Registration N/A, see methods.Competing Interest StatementCompeting interests: TJB and SH have corporate affiliation to ProgenaBiome, LLC and Topelia Therapeutics. S Dave has corporate affiliation to McKesson Specialty Health and North End Advisory, LLC. S Dolai has corporate affiliation to Topelia Therapeutics and Axent Medical. AWG has corporate affiliation to Topelia Therapeutics. RC and PAM have no disclosures. This study was funded and carried out by ProgenaBiome, LLC and Topelia Therapeutics. SH and TJB have patents relevant to the study.Clinical TrialNCT04949230Funding StatementThis study was funded by ProgenaBiome, LLC.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by E&I Review Services (https://www.eandireview.com/) as study # 210006All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.χ2test (Chi-Square Test)CDC(Center for Disease Control)CI(Confidence Interval)COVID-19(Coronavirus, SARS-COV-2)Hrs.(Hours)HAZDpaC(Hydroxychloroquine,Azithromycin,Vit D, Zinc Pack)H. pylori(Helicobacter pylori)ICT(Ivermectin Combination Therapy)PMH(Past Medical History)pt(point)pts(points)SEM(Standard Error of Mean)SOB(Shortness of breath)SpO2(Percent Saturation Peripheral Oxygen)temp(Body temperature in 0F)